Skip to main content

Kroin David's Form 4 filing

LB Pharmaceuticals Inc (LBRX) · filed Sep 16, 2025

Accession no.
0002015536-25-000007
Filed
Sep 16, 2025, 6:09 PM ET
Trade date
Sep 12, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market purchases total $40.0M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kroin DavidCIK 000139751310% Owner
Deep Track Capital, LPCIK 000185608310% Owner
Deep Track Biotechnology Master Fund, Ltd.CIK 000201553610% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 12, 2025Common StockCConversionAcquired+686,138––686,138Direct
Sep 12, 2025Common StockPPurchaseAcquired+2,000,000$15.00+$30,000,0002,686,138Direct
Sep 12, 2025Common StockPPurchaseAcquired+666,666$15.00+$9,999,990666,666Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 12, 2025Common StockCConversionDisposed−686,138––0Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)